Metagenomi Therapeutics reports Q1 2026 results today with a stock down 13% year-to-date, a short score in the 70th percentile, and a history of punishing moves after every print.
The lending market tells a story of rising short-side conviction. Short interest has climbed steadily over the past two weeks to roughly 5% of the free float — after a sharper pullback through April — and the ORTEX short score has ticked up four consecutive days to 70.3, its highest reading in recent history. The cost to borrow has risen more than 50% over the past month, now at 1.38%, though in absolute terms borrow remains accessible. Availability is not a constraint here; what's notable is the directional change — shorts have been rebuilding positions into this event after covering earlier in April.
The earnings history makes that positioning understandable. Every one of MGX's four most recent results events produced a negative price reaction. The worst came in November 2025, when the stock fell more than 22% on the day and extended those losses to nearly 27% over the following five sessions. March 2026 saw a 2.7% one-day drop and a 7.4% five-day loss. The pattern is consistent: the market has repeatedly found each print disappointing relative to expectations, and shorts have had little reason to reduce exposure.
The bull case rests on the science. Metagenomi's gene-editing pipeline targets Hemophilia A and cardiovascular disease, and preclinical data — including durable FVIII levels of 80% in non-human primates over 19 months — has attracted institutional attention. Bayer holds just over 10% of the company, and Renaissance Technologies nearly doubled its position by end of 2025. Bears point to the recurring net losses (Q2 2025 loss was $19.9 million, or $0.54 per share), the risk of clinical delays, and the dilution overhang that has kept the stock anchored far below its cash value. All available analyst data dates from August 2025 or earlier, so treating any specific price target as current would be misleading — but the direction of travel from that period was uniformly lower, with multiple firms cutting targets while holding Buy ratings. That combination — optimistic on the science, skeptical on the near-term setup — captures the fundamental tension heading into today.
Today's print tests whether Metagenomi can offer any concrete update on clinical timelines or partnership progress that might break the established pattern of post-earnings selling.
See the live data behind this article on ORTEX.
Open MGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
